利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.021 秒)

    TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANT
    1.
    发明公开
    TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANT 审中-公开

    公开(公告)号：US20240156806A1

    公开(公告)日：2024-05-16

    申请号：US18496134

    申请日：2023-10-27

    申请人： Corcept Therapeutics Incorporated

    发明人： Grace Mann ,  Iulia Cristina Tudor ,  William Guyer ,  Hazel Hunt ,  Joseph Custodio

    IPC分类号： A61K31/4738 ,  A61K31/4152 ,  A61K31/428 ,  A61P25/28

    CPC分类号： A61K31/4738 ,  A61K31/4152 ,  A61K31/428 ,  A61P25/28

    摘要： Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fused azadecalin compound is dazucorilant: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl) (pyridin-2-yl)methanone, having the chemical structure illustrated as




    Suitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food, or with water, or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2-fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration, enteral administration, or other administration. Pharmaceutical compositions comprising dazucorilant are useful in the treatment of patients suffering from ALS. Suitable pharmaceutical compositions comprising dazucorilant include, e.g., pharmaceutical compositions for oral administration and pharmaceutical compositions for enteral administration.

    METHODS OF TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN WITH MIRICORILANT
    2.
    发明公开
    METHODS OF TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN WITH MIRICORILANT 审中-公开

    公开(公告)号：US20240261287A1

    公开(公告)日：2024-08-08

    申请号：US18412258

    申请日：2024-01-12

    申请人： Corcept Therapeutics Incorporated

    发明人： Ada Lee ,  Joseph Belanoff ,  Hazel Hunt

    IPC分类号： A61K31/513 ,  A61P3/04

    CPC分类号： A61K31/513 ,  A61P3/04

    摘要： Methods and compositions for treating a subject at risk of, or suffering from antipsychotic-induced weight gain are disclosed. The methods include administration of a cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) such as miricorilant (CORT118335) to a patient receiving, or who has received, or who is expected to receive, an antipsychotic drug such as olanzapine, risperidone, clozapine, or other weight-inducing antipsychotic medication. The GRM (e.g., miricorilant) may be orally administered. Administration of such a GRM along with antipsychotic medication may reduce the amount of weight, or reduce the rate of weight gain, or prevent weight gain, otherwise due to antipsychotic medication alone. The methods may reverse weight gain in a patient previously administered antipsychotic medication. Administration of such a GRM with antipsychotic medication may reduce, or reduce gain in, or prevent gain in, or reverse gain in, insulin resistance or blood levels of liver enzymes (AST, ALT), triglycerides, or insulin.

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
    3.
    发明授权
    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 有权

    公开(公告)号：US11944617B2

    公开(公告)日：2024-04-02

    申请号：US17672380

    申请日：2022-02-15

    申请人： Corcept Therapeutics Incorporated

    发明人： Hazel Hunt ,  Joseph Custodio

    IPC分类号： A61K31/4725 ,  A61K31/337 ,  A61P35/00

    CPC分类号： A61K31/4725 ,  A61K31/337 ,  A61P35/00

    摘要： Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein.
    Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant.
    Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone. Relacorilant and such reduced doses of paclitaxel may be co-administered to treat cancer, e.g., ovarian or pancreatic cancer.

    Methods of treating antipsychotic-induced weight gain with miricorilant
    4.
    发明授权
    Methods of treating antipsychotic-induced weight gain with miricorilant 有权

    公开(公告)号：US11903945B2

    公开(公告)日：2024-02-20

    申请号：US17119582

    申请日：2020-12-11

    申请人： Corcept Therapeutics Incorporated

    发明人： Ada Lee ,  Joseph Belanoff ,  Hazel Hunt

    IPC分类号： A61K31/513 ,  A61K31/551 ,  A61P3/04

    CPC分类号： A61K31/513 ,  A61P3/04

    摘要： Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant Methods and compositions for treating a subject at risk of, or suffering from antipsychotic-induced weight gain are disclosed. The methods include administration of a cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) such as miricorilant (CORT118335) to a patient receiving, or who has received, or who is expected to receive, an antipsychotic drug such as olanzapine, risperidone, clozapine, or other weight-inducing antipsychotic medication. The GRM (e.g., miricorilant) may be orally administered. Administration of such a GRM along with antipsychotic medication may reduce the amount of weight, or reduce the rate of weight gain, or prevent weight gain, otherwise due to antipsychotic medication alone. The methods may reverse weight gain in a patient previously administered antipsychotic medication. Administration of such a GRM with antipsychotic medication may reduce, or reduce gain in, or prevent gain in, or reverse gain in, insulin resistance or blood levels of liver enzymes (AST, ALT), triglycerides, or insulin.

    CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND PACLITAXEL, A DUAL SUBSTRATE OF CYP2C8 AND CYP3A4
    7.
    发明申请
    CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND PACLITAXEL, A DUAL SUBSTRATE OF CYP2C8 AND CYP3A4 有权

    公开(公告)号：US20220184061A1

    公开(公告)日：2022-06-16

    申请号：US17672380

    申请日：2022-02-15

    申请人： Corcept Therapeutics Incorporated

    发明人： Hazel Hunt ,  Joseph Custodio

    IPC分类号： A61K31/4725 ,  A61P35/00 ,  A61K31/337

    摘要： Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein.
    Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant.
    Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone. Relacorilant and such reduced doses of paclitaxel may be co-administered to treat cancer, e.g., ovarian or pancreatic cancer.

    Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant
    8.
    发明申请
    Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant 有权

    公开(公告)号：US20210177848A1

    公开(公告)日：2021-06-17

    申请号：US17119582

    申请日：2020-12-11

    申请人： Corcept Therapeutics Incorporated

    发明人： Ada Lee ,  Joseph Belanoff ,  Hazel Hunt

    IPC分类号： A61K31/513 ,  A61P3/04

    摘要： Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant Methods and compositions for treating a subject at risk of, or suffering from antipsychotic-induced weight gain are disclosed. The methods include administration of a cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) such as miricorilant (CORT118335) to a patient receiving, or who has received, or who is expected to receive, an antipsychotic drug such as olanzapine, risperidone, clozapine, or other weight-inducing antipsychotic medication. The GRM (e.g., miricorilant) may be orally administered. Administration of such a GRM along with antipsychotic medication may reduce the amount of weight, or reduce the rate of weight gain, or prevent weight gain, otherwise due to antipsychotic medication alone. The methods may reverse weight gain in a patient previously administered antipsychotic medication. Administration of such a GRM with antipsychotic medication may reduce, or reduce gain in, or prevent gain in, or reverse gain in, insulin resistance or blood levels of liver enzymes (AST, ALT), triglycerides, or insulin.